The effectiveness of minimally invasive surgical treatments with rezūm system for benign prostatic hyperplasia: a systematic review and meta-analysis
Abstract
Introduction: Benign prostatic hyperplasia (BPH) is a common chronic condition frequently associated with the progressive development of voiding and obstructive lower urinary tract symptoms (LUTSs). Objective: This research aims to assess the effectiveness of the Rezūm system for BPH. Material & Methods: A literature search was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Clinical baseline characteristics, international prostate symptom score (IPSS), maximum flow rate (Qmax), postvoid residual (PVR), and quality of life (QoL) were analyzed using Revman 5.3. The risk of bias assessments was conducted by two independent authors and resolved through discussion. Results: A total of 288 studies were retrieved from PubMed, Cochrane, and Google Scholar. Four studies, including 590 patients, were analyzed, with a follow-up period of up to 12 months after treatment using the Rezūm system. The mean (SD) change from baseline to follow-up in IPSS improved from 20.58 (5.9) to 9.53 (6.7); Qmax increased from 9.2 (3.2) to 13.48 (6.5); PVR decreased from 128.2 (137.8) to 76.0 (88.8); and QoL improved from 4.6 (1.2) to 2.0 (1.4). The greatest improvement was observed in QoL (56.52%) followed by IPSS (55.88%), Qmax (46.74%), and PVR (40.72%). Conclusion: The Rezūm system is an effective therapy for BPH, providing significant relief of LUTSs.
Keywords: Benign prostatic hyperplasia, LUTS, Rezūm system
How strong is the evidence?
Evidence Hub reads this as a meta-analysis. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 590 participants or records.
Read the paper
Related studies
- Erectile dysfunction
- Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit
- Alpha1-adrenoceptor subtypes and lower urinary tract symptoms
- Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets
- Chronic bladder ischemia and oxidative stress: New pharmacotherapeutic targets for lower urinary tract symptoms
- The role of prostate inflammation and fibrosis in lower urinary tract symptoms
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.